Low serum magnesium and 1-year mortality in alcohol withdrawal syndrome by Maguire, Donogh et al.
Low serum magnesium and 1-year mortality in Alcohol Withdrawal Syndrome 
Donogh Maguire1,2,§, David P Ross1,2, Dinesh Talwar 3, Ewan Forrest 4, Hina Naz Abbasi 5, John-
Paul Leach 5,6, Marylynne Woods 6, Luke Y Zhu 6, Scott Dickson 6, Tong Kwok 6, Isla Waterson 6, 
George Benson 7, Benjamin Scally 8, David Young 9, Donald C McMillan 2 
1. Emergency Medicine Department, Glasgow Royal infirmary, G4 0SF, UK 
2. Academic Unit of Surgery, School of Medicine, University of Glasgow, New Lister Building, 
Royal Infirmary, Glasgow, G31 2ER, UK 
3. The Scottish Trace Element and Micronutrient Reference Laboratory, Department of 
Biochemistry, Royal Infirmary, Glasgow, G31 2ER, UK 
4. Department of Gastroenterology, Glasgow Royal Infirmary, G4 0SF 
5. Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University 
Hospital, 1345 Govan Rd, Glasgow G51 4TF 
6. University of Glasgow, School of Medicine Veterinary and Life Sciences, Wolfson Medical 
School Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ 
7. Alcohol and Drug Addiction Treatment Department, Glasgow Royal Infirmary, Glasgow, G4 
0SF 
8. Emergency Department, Edinburgh Royal Infirmary, 51 Little France Crescent, 
Edinburgh, EH16 4SA 
9. Department of Mathematics and Statistics, University of Strathclyde, Glasgow, G1 1XH 
§ Corresponding author: Dr. Donogh Maguire, Emergency Medicine Department, Glasgow Royal 
Infirmary, 84 Castle Street, Glasgow, G4 0SF 
Donogh.Maguire@glasgow.ac.uk                                                    Telephone: 0044-141-2115166 
 
 2 
Abstract  
Background: 
In 2014, the WHO reported that 6% all deaths were attributable to excess alcohol consumption. The 
aim of the present study was to examine the relationship between serum magnesium concentrations 
and mortality in patients with alcohol withdrawal syndrome (AWS). 
Methods: 
A retrospective review of 700 patients with documented evidence of previous AWS indicating a 
requirement for benzodiazepine prophylaxis or evidence of alcohol withdrawal syndrome between 
November 2014 and March 2015.  
Results: 
Of 380 patients included in the sample analysis, 64 (17%) were dead at 1 year following the time of 
treatment for AWS. The majority of patients had been prescribed thiamine (77%) and a proton 
pump inhibitor (66%).  In contrast, the majority of patients had low circulating magnesium 
concentrations (<0.75mmol/l) (64%) and had not been prescribed magnesium (90%).  The median 
age of death at one year was 55 years (p=0.002). On univariate analysis, age (p<0.05), GMAWS 
(p<0.05), BDZ (p<0.05), bilirubin (p<0.001), alkaline phosphatase (p<0.001), albumin (p<0.001), 
CRP (p<0.05), AST:ALT ratio >2 (p<0.001), sodium (p<0.05), magnesium (p<0.001), platelets 
(p<0.05) and the use of proton pump inhibitor medication (p<0.001) were associated with death at 1 
year.  On multivariate binary logistic regression analysis, age >50 years (OR 3.37, 95%CI 1.52-
7.48, p<0.01), AST:ALT ratio >2 (OR 3.10, 95%CI 1.38-6.94, p<0.01) and magnesium <0.75 
mmol/L (OR 4.11, 95%CI 1.3-12.8, p<0.05) remained independently associated with death at 1 
year.   
Conclusion: 
Overall, 1-year mortality was significantly higher among those patients who were magnesium 
deficient (<0.75 mmol/L) when compared to those who were replete (> 0.75 mmol/L) (p<0.001).  
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Introduction   
In 2014, the WHO reported that 5% of the global burden of disease and 6% all deaths were 
attributable to excess alcohol consumption (1).  Some areas of the world are more severely affected 
than others (2). For example, over half of all deaths in Russia between 1990 and 2001 were 
attributed to alcohol (3), while in Scotland it is estimated that one in four adults currently consume 
alcohol at harmful or hazardous levels (4). Despite public health measures, alcohol consumption has 
continued to rise in the U.K. and U.S.A. over the past three decades (1, 4, 5), while alcohol related 
mortality among women has more than doubled in Scotland over the past decade (6). 
Recent recognition of alcohol as a carcinogen may have contributed to these 
epidemiological estimates of alcohol related morbidity and mortality (7), however little data is 
available in the literature relating to expected mortality for patients diagnosed with severe alcohol 
use disorder, as defined by a simple tool such as the Focused Alcohol Screening Test (FAST) score 
or following an episode of acute alcohol withdrawal (8). The Glasgow Modified Alcohol 
Withdrawal Score (GMAWS) is a validated score of severity of alcohol withdrawal syndrome that 
allocates a score (0-2) to five clinical characteristics (tremor, anxiety, sweating, orientation, 
hallucinations) (8). The benzodiazepine treatment dose is titrated and the time interval to re-
administering the GMAWS scoring test are determined by the score achieved (i.e. the severity of 
alcohol withdrawal). A GMAWS > 4 is considered severe, and is approximately equivalent to a 
Clinical Institute Withdrawal Assessment - Alcohol Revised (CIWA-Ar) scale > 16 (8). 
It is reported that 40% of patients admitted to a general hospital and 33% of patients 
admitted to the intensive care unit (ICU), fulfil the criteria for diagnosis of alcohol use disorder (9). 
Alcohol withdrawal syndrome is reported to occur in 10% of patients who fulfil the criteria for 
alcohol use disorder patients (10). An episode of severe alcohol withdrawal syndrome is reported to 
extend the length of stay in hospital by a median of 4 days (11) and more than double the length of 
stay in ICU settings (12).  Indeed, patients who experience excited delirium are reported to have 
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20% higher acute mortality in a cardiac intensive care setting (12), and 37% mortality at 8 years 
(13), which is comparable to patients diagnosed with several severe malignant disease processes 
(14, 15).  
Alcohol exerts direct and indirect effects on cellular energy metabolism and alcohol use 
disorder is a complex psychological and pathophysiological problem. Nutritional and social factors 
may be protective or contributory, however a threshold may be reached beyond which alcohol 
related compromise of oxidative resilience manifests in accelerated organ/ system specific final 
common pathways of biochemical and clinical deterioration. The occurrence of alcohol withdrawal 
syndrome (AWS) may represent the crossing of that threshold. 
The aim of the present study was to examine the relationship between clinicopathological 
characteristics, circulating magnesium concentrations and 1- year mortality in patients with AWS. 
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Patients and methods 
A retrospective case-note review of electronic patient records of sequential patients, who 
were referred to the hospital addictions team between November 2014 and March 2015, was carried 
out (n=700).  The hospital Alcohol and Drugs Addiction Team in Glasgow Royal Infirmary (GRI) 
serves an urban population in the north and east of the city, which has a high burden of socio-
economic (SE) deprivation (6, 16). GRI is a general hospital that offers the full spectrum of adult 
acute receiving specialties to patients over 16 years old.  This review of patients was carried out as 
an audit and was approved by the Greater Glasgow and Clyde NHS Caldecott Guardian. 
The availability of age, sex, BMI and documented evidence of AWS were considered minimal criteria 
for inclusion (n=380). From the original cohort of 700 patients, 320 patients were excluded in the 
final analysis as they did not fulfil the entry criteria of either contemporaneous BMI (+/- 3 month 
time period from study related attendance) or documented evidence of AWS.  
Duplicate referrals were removed and data from the earliest time of referral was recorded. Data was 
analysed according to 1-year mortality and serum magnesium concentrations. Standard thresholds 
were applied to the data. Continuous data were analyzed using the Mann-Whitney U test and 
categorical data were analyzed using the Chi-squared test. Data that reached a p-value <0.10 on 
univariate analysis were included in the multivariate binary logistic regression analysis. Data was 
analyzed in SPSS (Version 24.0. SPSS Inc., Chicago, IL, USA). 
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Results 
Of the 700 patients, 380 patients fulfilled the criteria for inclusion with age, sex, BMI and 
documented evidence of alcohol withdrawal syndrome. The clinicopathological characteristics are 
shown in Table 1. The majority of patients were <50 years old (53%), male (76%), not underweight 
(80%), had a severe alcohol withdrawal score (GMAWS max score > 4) and the total ‘diazepam-
equivalent’ dose of benzodiazepine (BDZ) administered was less than 120mg (81%).  Of the 
laboratory analysis, the majority of patients had bilirubin (58%), alkaline phosphatase (71%), 
albumin (56%), CRP (57%), AST/ALT ratio (62%), glucose (66%), urea (66%), sodium (70%), 
potassium (76%), MCV (88%) and platelets (67%) within the laboratory reference range.  The 
majority of patients had been prescribed thiamine (77%) and a proton pump inhibitor (PPi) (66%).  
In contrast, the majority of patients had circulating magnesium concentrations that could be 
considered to be low (<0.75mmol/l) (64%) and had not been prescribed magnesium (90%).  When 
patients from this cohort were followed up at their next admission the majority of patients still had 
magnesium (65%) below the reference range (median = 0.69 mmol/L, range 0.32 – 0.97 mmol/L, 
median time interval between samples = 128 days) (Figure 1).  
At one year, 64 patients with AWS had died giving a mortality rate of 17%.  Sepsis (40%) 
and complications of chronic liver disease (36%) were the commonest causes of death (see Table 
2).  The relationship between 1-year mortality and clinicopathological characteristics are shown in 
Table 1.  On univariate analysis, age (p<0.05), GMAWS (p<0.05), BDZ (p<0.05), bilirubin 
(p<0.001), alkaline phosphatase (p<0.001), albumin (p<0.001), CRP (p<0.05), AST:ALT ratio 
(p<0.001), sodium (p<0.05), magnesium (p<0.001), platelets (p<0.05) and treatment with PPi’s 
(p<0.01) were associated with death at 1 year.  On multivariate binary logistic regression analysis, 
age >50 (OR 3.37, 95% CI 1.52-7.48, p<0.01), AST:ALT ratio >2 (OR 3.10, 95% CI 1.38-6.94, 
p<0.01) and magnesium <0.75 mmol/L (OR 4.11, 95% CI 1.3-12.8, p<0.05) remained 
independently associated with death at 1-year.  
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The majority of patients had a documented history of alcohol withdrawal seizures (54%) and 
5% of patients included in the present study had experienced a seizure in relation to the study 
related admission. No association was found between previous AWS seizure and 1-year mortality. 
The majority of patients (95%) presenting to the Emergency Department with AWS had a 
temperature <37.50C. The median temperature of patients was 36.20C (33 – 39.10C). No association 
between 1-year mortality or severity of AWS was found with temperature.  
The FIB4 score is a validated scoring system for severity of liver fibrosis (17). In this cohort 
of patients FIB4 >1.45 was associated with low serum magnesium concentrations (p<0.001), 1-year 
mortality (p<0.001), a documented history of chronic liver disease (p<0.01) and elevated plasma 
lactate (p<0.05). 
The relationship between low circulating magnesium concentrations and clinicopathological 
characteristics is shown in Table 3.  Low circulating magnesium concentrations were associated 
with a lower median GMAWS max (p<0.05), elevated bilirubin (p<0.01), elevated alkaline 
phosphatase (p<0.05), low albumin (p<0.001), elevated AST:ALT ratio (p<0.001), low sodium 
(p<0.001), low potassium (p<0.001), low platelets (p<0.001), elevated MCV (p<0.05), low follow-
up magnesium concentration (p<0.001), and no supplemental magnesium treatment (p<0.001).  The 
odds ratios for 1-year mortality associated with serum magnesium concentrations for patients with 
AWS in this study are shown in Table 4.   
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Discussion 
 In a comprehensive analysis of factors associated with 1-year mortality, the results of the 
present study show that the majority of patients with AWS had low magnesium concentrations at 
presentation and without treatment remained low on follow-up.  Furthermore, low magnesium was 
independently associated with increased risk of mortality (approximately 4 fold) at 1-year.  These 
results highlight the importance of a low circulating magnesium concentration and its lack of 
treatment in outcome of patients presenting with AWS. 
 Circulating magnesium concentrations are tightly regulated. However, there is on-going 
debate as to the serum magnesium concentration threshold below which a patient may be 
considered to be deficient (18, 19).  Most epidemiological studies have defined concentrations 
below 0.70mmol/l as “very low” (20-22) whilst others have suggested concentrations below 
0.75mmol/l as “low” (22, 23).  In the present study approximately 65% of patients with AWS had 
low circulating concentration of magnesium (< 0.75mmol/l) and this was independently associated 
with mortality.  In comparison and using the “low” threshold (< 0.75mmol/l), Zhang and co-
workers examined data from the NHANES epidemiologic follow-up study of more than 14,000 
apparently healthy subjects and reported that approximately 7% had a low circulating magnesium 
concentration, and this was associated with greater all cause mortality (22).  Therefore, since it is 
clear that low circulating magnesium concentrations are much more common in patients with AWS 
(24, 25), it is plausible that such low concentrations may contribute to mortality in this patient 
group.  
 The basis of such low concentrations of magnesium is not clear since only 1% of the whole 
body pool of magnesium is in the circulation and there is a tight homeostatic control of circulating 
magnesium concentrations (26). Furthermore, there is a poor correlation between circulating 
magnesium and dietary magnesium intake (27-29). Nevertheless, low circulating magnesium 
concentrations would suggest that there is a net redistribution of magnesium from the circulation to 
the cells.  
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 In the present study low circulating magnesium concentrations were associated with an 
elevated bilirubin, alkaline phosphatase and AST:ALT ratio. They were also associated with low 
platelets, albumin and potassium.  Taken together these results may suggest that low magnesium 
concentrations, given their independent prognostic value, compromise liver and renal function.  
Indeed, chronic alcohol use is recognised to damage liver cells as part of the detoxification process 
(30).  As part of substantial liver cell breakdown there will be an increase in circulating bilirubin, 
alkaline phosphatase and the AST:ALT ratio, and a reduction of albumin synthesis.  In addition, 
chronic alcohol use is recognised to cause tubular dysfunction in the kidney (24, 31). Such renal 
dysfunction results in an increase in the loss of magnesium, potassium and albumin in the urine 
(31).  Clearly, low magnesium, given its role as an enzyme cofactor in the cytoplasm and 
mitochondria of the liver and the kidney may further compromise the ability of these organs to 
withstand chronic exposure to alcohol (32).  Specifically, alcohol mediated magnesium depletion 
may result, through compromised enzyme function, in a cycle of reduced ATP production (33), 
magnesium extrusion (34), loss of mitochondrial inner-membrane potential and cell death (35). 
 In the present study it was of interest that thiamine, although rarely measured (only 1 patient 
in the cohort had a thiamine measurement), was frequently administered to patients with AWS.  In 
contrast, magnesium was frequently measured but rarely administered, particularly in those patients 
with a low circulating magnesium concentration.  The reasons for this clinical paradox are not clear 
but in the case of thiamine it probably reflects the delay in getting thiamine results (approximately 
two weeks) and the established clinical appreciation of the importance of thiamine deficiency in 
exacerbating symptoms in patients with AWS.  In contrast, in the case of magnesium, although 
results are obtained within hours, the clinical appreciation of the importance of a low magnesium 
concentration is probably less well-established in patients with AWS.  Therefore, further studies are 
required to clarify the relative importance of thiamine and magnesium measurement and treatment 
in patients with AWS.  Nonetheless, on the basis of the present findings, it may be considered that 
magnesium may represent a potential therapeutic target in this patient group. As such, oral 
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magnesium supplementation represents a potential low-cost treatment option. However, it should be 
recognized that gastrointestinal side effects of oral magnesium supplementation may compromise 
patient compliance. Further studies are therefore required to clarify the dose and frequency of oral 
magnesium supplementation that may optimize patient compliance. 
The present study had a number of limitations.  In particular, the nature of observational 
studies even with longitudinal follow-up precludes establishing a causal relationship between a low 
circulating magnesium concentration and mortality.  Further prospective studies including 
randomised clinical trials are required to test and establish such a causal relationship.  
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Conclusion 
  In summary, the results of the present study implicate low circulating magnesium 
concentrations (<0.75 mmol/L), and the lack of magnesium treatment, in short-term mortality for 
patients presenting with alcohol withdrawal syndrome. 
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Table 1.  The relationship between clinicopathological characteristics and 1-year mortality in patients with AWS (n=380) 
  
1-year Mortality 
Univariate analysis 
1-year Mortality 
Multivariate analysis 
Alive 
(n = 316) 
Dead 
(n = 64) 
P-value
1 Odds 
Ratio 
95% CI P-value2 
Age (years) 47 (21 – 85) 54 (29 – 88) 0.002 
   
Age (<50 / >50 y) 176/140 24/40 0.008 3.37 (1.52 – 7.48) 0.003 
Male/ Female 243/73 45/19 0.239 
   
BMI (kg/m
2
) 23.6 (14 – 52.5) 22.9 (14.4 -40.4) 0.542 
   
BMI  (> 20 / < 20kg/m
2
) 256/60 47/17 0.170 
   
Clinical 
      
Alcohol intake (U/Day) 30 (1 – 120) (a) 23 (3 - 80) (a) 0.133 
   
FAST (<9/>9) 24/212 5/35 0.657 
   
GMAWS (at presentation) 2 (0 - 9) 2 (0 - 6) 0.307 
   
GMAWS (max) 4 (0 – 10) 3 (0 - 8) 0.055 
   
GMAWS max (<4 / > 4) 112/180 32/26 0.020       
BDZ total (mg) 170 (10 – 1130) 110 (10 - 570) 0.052 
   
BDZ total (<120 / >120 mg) 181/135 46/18 0.034 0.452 (0.199 – 1.03) 0.058 
Laboratory 
      
Bilirubin (umol/L) 16 (2 - 309) 29 (5 - 462) <0.001 
   
Bilirubin (< 20 / > 20 umol/L) 197/117 24/39 <0.001 
   
Alk phos (U/L) 96 (31 - 524) 129 (43 - 475) <0.001 
   
Alk phos (<130/ >130 U/L) 237/77 33/30 <0.001 2.25 (0.959 – 5.30)  0.062 
Albumin (g/L) 36 (16 - 53) 29 (13 - 48) <0.001 
   
Albumin (> 35 / < 35 g/L) 193/121 18/45 <0.001 2.25 (0.959 – 5.30) 0.062 
CRP (mg/L) 5 (<1 - 286) 10 (<1 - 221) <0.001 
   
CRP (<10 / > 10 mg/L) 189/118 29/33 0.031 
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AST: ALT  1.5 (0.5 - 6.6) 2.3 (0.9 - 7.4) <0.001 
   
AST: ALT (<2 / >2) 214/89 23/40 <0.001 3.10 (1.38 – 6.94) 0.006 
GGT (U/L) 164 (7 - 2889) 221 (42 - 2281) 0.337 
   
GGT (<50/ >50 U/L) 21/86 2/21 0.220 
   
Glucose (mmol/L) 5.8 (3.0 - 81) 6.1 (2.7 - 30.8) 0.810 
   
Glucose (< 7/ >7 mmol/L) 205/54 47/11 0.311 
   
Lactate (mmol/L) 2.3 (0.4 - 19.2) 2.8 (1.0 - 12.9) 0.212 
   
Lactate (<2.0/>
 
2.0 mmol/L) 27/86 3/21 0.222 
   
Urea (mmol/L) 3.3 (0.5 – 21.2) 3.1 (0.8 – 78.0) 0.341 
   
Urea (>2.5 / < 2.5 mmol/L) 209/91 40/16 0.755       
Sodium
 
(mmol/L) 138 (106 - 165) 136 (105 - 149) <0.001 
   
Sodium
 
(>135 /<135 mmol/L) 230/84 37/26 0.021       
Potassium (mmol/L) 3.9 (2.3 - 6.2) 4.2 (2.2 - 7.3) 0.434 
   
Potassium (>3.5 / <3.5 mmol/L) 245/54 45/16 0.142       
Magnesium (mmol/L) 0.70 (0.25 – 1.19) 0.62 (0.28 – 0.95) <0.001 
   
Magnesium (> 0.75 / < 0.75 mmol/L) 93/135 6/42 <0.001 4.11 (1.3 – 12.8) 0.015 
MCV (fl) 95.1 (60.1 – 116.3) 94.8 (70.6– 123.5) 0.854 
   
MCV (<96 / > 96 fl) 156/143 34/27 0.464 
   
Platelets (10
9
/L) 201 (15 - 725) 158 (29 – 515) 0.003 
   
Platelets (>150 / <150 x 10
9
/L) 219/95 35/28 0.029 
   
Medications 
      
Thiamine (Yes/No) 233/51 59/3 0.477 
   
Magnesium
 
(Yes/No) 24/264 9/48 0.034 
   
PPi (Yes/No) 196/119 53/10 0.001 2.45 (0.96 – 6.25) 0.062 
 
Continuous data are presented as median values, ranges are presented in parenthesis. 
1Continuous data were analysed with Mann-Whitney U test and categorical data were analysed with Chi-squared test 
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2 Binary logistic regression analysis 
(a) alive: n = 226; dead: n = 44 
 
 
 
 
 
 
 
 
Table 2. Cause of death in patients (n=64) within 1-year in patients with AWS (n=380) 
Cause of death at 1-year in patients with AWS  Total 
Cancer 3 
Cardiovascular (AMI, PE) 3 
Coma – cause unknown 2 
Deliberate self poisoning  1 
Deliberate self harm  1 
Trauma – accidental - brain injury 1 
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ALD complications e.g. hepatic encephalopathy, hepatorenal syndrome, 
bleeding oesophageal varices 
23 
Sepsis 25 
Seizure 3 
Acute mesenteric ischaemia 1 
COPD 1 
 
 
 
 
 
 
Table 3.  The relationship between low circulating magnesium concentrations and clinicopathological characteristics in patients with AWS (n=275) 
  Magnesium (mmol/L) 
> 0.75 
(n = 98) 
< 0.75 
(n = 177) 
P-value
1 
Age (< 50 / > 50 y) 56/42 92/85 0.337 
Male/ Female 77/21 128/49 0.175 
BMI  (> 20 / < 20kg/m
2
) 78/20 134/43 0.505 
Dead at 1-year (Yes/No) 6/92 42/135 < 0.001 
Clinical 
   
Alcohol intake (U/Day) 28 (2 – 120) (a) 30 (1-120) (b) 0.368 
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FAST (< 9/ > 9) 4/70 13/110 0.212 
GMAWS (at presentation) (<4 / > 4) 55/39 130/44 0.296 
GMAWS (max) 4 (0 – 10) 3 (0-9) 0.338 
GMAWS max (< 4 / > 4) 28/60 81/86 0.011 
BDZ total (mg) 120 (10 – 1130) 90 (10- 840) 0.241 
BDZ total (< 120 / > 120 mg) 52/46 107/70 0.195 
Laboratory 
   
Bilirubin (< 20 / > 20 umol/L) 66/31 82/94 <0.001 
Alk phos (< 130/ > 130 U/L) 77/20 114/62 0.007 
Albumin (> 35 / < 35 g/L) 65/32 74/102 <0.001 
CRP (< 10 / > 10 mg/L) 58/37 90/83 0.118 
AST: ALT (<2 / > 2) 68/25 90/81 0.001 
Glucose (< 7 / > 7 mmol/L) 68/13 117/38 0.176 
Lactate (< 2.0 / >
 
2.0 mmol/L) 9/25 15/58 0.496 
Urea (> 2.5 / < 2.5 mmol/L) 67/26 102/63 0.117 
Sodium (> 135 /< 135 mmol/L) 72/25 113/63 0.108 
Potassium (> 3.5 / < 3.5 mmol/L) 80/9 120/50 0.001 
Follow-up Magnesium
 
 (> 0.75 / < 0.75 mmol/L) 45/25 27/110 <0.001 
MCV (< 96 / > 96 fl) 56/38 76/89 0.031 
Platelets (> 150 / <150 x 10
9
/L) 76/22 101/74 0.001 
Medications 
   
Thiamine (Yes/No) 75/13 142/21 0.821 
Magnesium (Yes/No) 1/89 31/122 <0.001 
PPi (Yes/No) 64/34 125/50 0.256 
 
1 Continuous data were analysed with Mann-Whitney U test and categorical data were analysed with Chi-squared test 
(a) n = 69 (b) n = 125 
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Focused Alcohol Screening Test (FAST); Glasgow Modified Alcohol Withdrawal Score (GMAWS); Diazepam equivalent dose of 
benzodiazepine (BDZ); Proton pump inhibitor (PPi) 
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Figure 1. Change in serum Mg2+ concentrations for patients with AWS at first admission and next 
admission. 
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Table 4. Odds ratio of death at 1-year in relation to serum magnesium thresholds (n=275) 
Serum Magnesium 
(mmol/L) 
Odds Ratio 
Death at 1-year 
p-value1 
0.60 2.50 0.004 
0.65 2.50 0.004 
0.70 4.70 <0.001 
0.75 5.90 <0.001 
0.80 4.50 0.006 
0.85 3.00 0.079 
 
1 Univariate logistic regression analysis 
